FEED
****Sponsored Content by TD Media, LLC
A leading nonprofit health system running 12 hospitals across Virginia and North Carolina recently made the platform its standardized protocol for bedside feeding tube placement, extending the relationship through 2028
The ENvue System is FDA 510(k) cleared and currently in use at hospitals across the United States
According to Yahoo, FEED on has just over 6M Shares
_________________________
Hello Everyone,
We have something for you to keep an eye on for today's session. Research this one right away.
The real story is in the float. According to Yahoo, FEED on has just over 6M Shares.
5 Catalysts to pay attention to for ENvue Medical, Inc. (Nasdaq: FEED) for today:
1. Three Distinct Platforms in One Company: ENvue Medical isn't a one-product story—it runs three separate device platforms targeting feeding tube placement, chronic pain, and hospital-acquired infections.
2. GPS-Style Feeding Tube Navigation: The ENvue System uses electromagnetic field technology and built-in sensors to create a real-time body map, showing providers exactly where a feeding tube is traveling—like GPS for the inside of the body.
3. A Genuine Patient-Safety Problem: Misplaced feeding tubes can enter the airway instead of the digestive tract, with consequences that can be severe or even fatal. The system's red-arrow alerts warn when the tube approaches the airway.
4. FDA-Cleared and Already in Hospitals: The ENvue System is FDA 510(k) cleared and currently in use at hospitals across the United States.
5. Becoming Standard of Care: A leading nonprofit health system running 12 hospitals across Virginia and North Carolina recently made the platform its standardized protocol for bedside feeding tube placement, extending the relationship through 2028.
Across the United States, hospitals perform more than 13M feeding tube placements every year — yet a staggering 85% of those procedures are still performed blindly, without any real-time visual guidance, forcing clinicians to wait on radiology confirmation before a single drop of nutrition can reach a patient.
(FEED) built its platform specifically to fix that problem — and this week, independent peer-reviewed science confirmed that it works.
A study just published in the official journal of the American Association of Critical Care Nurses showed the ENvue™ Navigation Platform saved over 350 nursing hours in year one, cut repeat imaging by 20%, and reduced hospital-acquired aspiration pneumonia by 20% across a multi-hospital health system.
Those aren't projections. They are real-world, independently documented clinical outcomes.
The commercial story around this name has been developing fast — and there are now even more reasons to have FEED on your radar this morning.
The company operates two distinct technology platforms that together address a wide range of clinical and home-care needs.
The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system that assists clinicians in placing nasoenteral feeding tubes at the bedside with real-time visual guidance.
The system is FDA 510(k) cleared for adult use and is now commercially deployed across 40 U.S. hospitals, generating recurring consumable revenue as clinicians integrate it into their daily workflow.
The company's second platform, the Acoustic Therapeutic Platform, includes PainShield® and UroShield® — devices utilizing proprietary low-intensity surface acoustic wave (SAW) technology designed for pain reduction, biofilm disruption, and bacterial colonization prevention in home and clinical settings.
UroShield recently secured reimbursement approval in the UK, adding an international revenue channel through distributor Peak Medical.
Leadership is anchored by Doron Besser, MD, Chief Executive Officer, with Marc Waldman serving as VP of Commercial — bringing over 35 years of medical device commercial leadership to the role. David Johnson serves as Chairman of the Board.
ENvue Medical (NASDAQ: FEED) Just Unlocked the Recurring Revenue Story Investors Have Been Waiting For
ENvue Medical has just introduced Ask Oscar™, an AI-powered training platform that goes straight at the single biggest bottleneck standing between any medical technology and full-scale hospital adoption: training. And the way management is framing it, this isn't a side feature — it's the layer that changes the entire economics of how ENvue scales.
Here's the problem Ask Oscar was built to solve. Hospitals are stretched thin, clinicians rotate shifts constantly, and every new competency requirement means pulling a specialist on-site to train nurses and dietitians in person. That bottleneck has quietly capped how fast even great medical technology can spread through a health system. Ask Oscar removes it entirely by letting clinicians train independently, on their own schedule, with the platform monitoring procedural performance in real time, catching deviations, and delivering immediate corrective coaching — no educator required to be standing in the room.
That alone would be a meaningful operational upgrade. But the real signal for investors is what CEO Doron Besser is saying about the business model underneath it: Ask Oscar is expected to be commercially available within the coming months across ENvue's entire installed hospital base, and management is positioning it as a scalable, recurring revenue stream layered directly on top of the existing Navigation Platform footprint. In other words, ENvue isn't just selling more hardware into hospitals — it's building a second revenue engine on top of the customers it's already won.
And Ask Oscar isn't a standalone side project. It's built on ENvue's existing navigation and training infrastructure, and every session run through the platform generates data that feeds an intelligence layer designed to support the Company's broader roadmap — including ENvue Drive, its patent-pending robotic-assisted feeding tube placement initiative. Management describes the foundation here as extending well beyond training itself, toward future intelligent guidance and advanced procedural assistance across the entire ENvue ecosystem.
This launch also doesn't happen in a vacuum — it lands right behind a landmark independent, peer-reviewed study published in Critical Care Nurse that put hard numbers behind the ENvue Navigation Platform's clinical impact: zero lung placements across 531 consecutive procedures, a 67% reduction in ventilator-associated pneumonia, a staggering 4,320% increase in post-pyloric feeding access, more than 350 nursing hours freed annually, and over $1.5 million in annual cost avoidance within a single health system. That's the kind of validation that turns a sales conversation into a standard-of-care decision — and now ENvue is pairing that clinical credibility with an AI layer designed to make adoption faster and stickier across every account it touches.
Put simply: ENvue just gave hospitals a faster way to say yes, and gave itself a new way to get paid for it.
Burn ICU Expansion Signals Growing Clinical Versatility
Two days after that publication, on June 5, 2026, FEED announced that a major U.S. academic health network has expanded its use of the ENvue™ Navigation Platform into its American Burn Association-verified burn intensive care unit — marking the second deployment within the same health system.
Burn ICU patients represent one of the most clinically challenging and vulnerable populations in hospital medicine. Feeding tube placement in this setting carries elevated risk, and the decision to expand an existing platform relationship into the burn ICU — rather than simply maintaining current deployments — signals a level of institutional trust that goes well beyond standard contract renewals.
CEO Doron Besser, MD, addressed it directly: "We believe that this health network's decision to bring the ENvue Navigation Platform into their burn ICU speaks directly to the clinical versatility of our platform and institutional trust that we have earned with this network."
The fact that this expansion occurred within a health system already using the platform — and came just days after peer-reviewed clinical results from a multi-hospital Inova deployment — suggests a pattern of deepening institutional commitment rather than one-off adoption.
Commercial Momentum: The Bigger Picture
Before these two most recent developments, FEED had already been building a compelling commercial foundation:
On May 12, 2026, FEED announced that its ENvue™ Navigation Platform was adopted as the standardized protocol for bedside feeding tube placement across a 12-hospital integrated non-pro-fit health network in Virginia and North Carolina — a three-year renewal running through 2028. Standardized protocol status means the platform is embedded directly into clinical workflow as the method of care, driving consistent utilization across the network rather than simply being available for optional use.
On May 7, 2026, FEED locked in a three-year GPO purchasing agreement renewal tied to one of the largest non-pro-fit health systems in the U.S. — encompassing more than 90 hospitals across 17 states.
Any participating hospital can now move directly to adoption without navigating lengthy value analysis committee approvals. CEO Doron Besser, MD, stated the arrangement makes the platform "one clinical decision away from adoption" at any participating facility.
FEED also holds two recently issued USPTO Notices of Allowance — one covering a next-generation feeding tube combining electromagnetic navigation with a distal-tip camera, and a second covering SAW technology applied to transdermal compound delivery — broadening the IP portfolio into pain management, neurology, and inflammation applications.
NEWS
June 9, 2026
ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
June 5, 2026
ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network
June 3, 2026
ENvue Medical Announces Publication of Landmark Independent Study Highlighting Significant Safety, Time-, and Cost-Saving Benefits of ENvue Navigation Platform in Multi-Hospital System
May 19, 2026
ENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026
May 12, 2026
ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
May 8, 2026
ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology
May 7, 2026
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
April 16, 2026
ENvue Issues Stockholder Letter & Provides Corporate Update
March 24, 2026
ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39
MANAGEMENT
Doron Besser, M.D.
Chief Executive Officer
Doron Besser is the CEO of ENvue Medical and NanoVibronix (Nasdaq: NAOV), overseeing the integration of the two divisions: electromagnetic navigation for enteral feeding (ENvue) and non-invasive therapeutic devices for pain and urology (NanoVibronix).
Doron is continuing the advancement and commercialization of ENvue navigation system for enteral feeding, leading global strategy, clinical education, commercialization in the U.S. and ROW, and expansion into new applications including pediatrics and vascular access.
Prior to managing both divisions, Doron co-founded and managed ENvizion Medical and Swing Medical, a private equity investment fund. Doron guided ENvizion Medical from concept to FDA clearance, built U.S. clinical adoption, and launched the ENvue system into hospitals as a next-generation navigation platform.
Doron also co-founded and led NutriSeal, a company focused on preventing nasoenteral-induced gastric reflux and ventilator-associated pneumonia (VAP). Prior to NutriSeal, Doron served as CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at super Dimension, a leader in minimally-invasive pulmonology devices. Doron helped lead super Dimension from its inception, serving on the core team that identified opportunities within the pulmonology market. In 2012, Covidien acquired superDimension for ~$300 million.
As a seasoned entrepreneur, Doron specializes in identifying breakthrough technologies and developing them throughout all product development phases, including international sales and marketing activities.
He holds a Doctor of Medicine degree from Munich’s Ludwig-Maximilians University.
Zenya Gorlik
VP R&D
Zenya Gorlik is a seasoned software expert with over 20 years of experience in developing large-scale multidisciplinary projects in military and medical industries from geographic information systems for intelligence to MRI medical devices and beyond. He specializes in managing projects end-to-end from concept to delivery.
Before joining ENvue Medical in 2021, Zenya served as senior software engineer and team leader at Camtek, ImageSat International, and Aspect Imaging, as software consultant at CodeValue, and more.
He holds a BA in mathematics and computer science from Haifa University, and is certified as a systems analysis engineer by the Technion Institute of Technology.
Anat Hofshi, PhD
VP Clinical Affairs & Product
With a great belief in technologies that can improve patient safety, Dr. Hofshi joined ENvue Medical in 2016 to lead the clinical activities and trials required to finalize the R&D phase and to commercialize the ENvue system in the US. Dr. Hofshi brings outstanding ability to interconnect between different disciplines areas and a high level of practical and hands-on skills.
Previous to her joining ENvue, Dr. Hofshi, served as a Project Leader at B.G. Guard and Carmel StemSense, startup companies in the field of Diabetics.
Dr. Hofshi holds a B.S.c in Biotechnology and Food engineering and a PhD from the Department of Physiology and Biophysics, Technion Institute, specializing in Electrophysiology, Stem Cells and Cardiovascular Regenerative Medicine. Dr. Hofshi received many awards and honors for her scientific accomplishments (Wolf, etc.).
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, TD MEDIA, LLC FOR A ONE DAY FEED PROFILE ON 7/8/26.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.